CD14 and LBP in endotoxemia and infections caused by Gram-negative bacteria
Open Access
- 1 December 2001
- journal article
- other
- Published by SAGE Publications in Innate Immunity
- Vol. 7 (6) , 439-441
- https://doi.org/10.1177/09680519010070060701
Abstract
It is now well recognized that plasma LPS-binding protein (LBP) and membrane CD14 present at the surface of cells of the myelo/monocytic lineage are central molecules of the innate immune system, in response to LPS or to bacterial products. This paper reviews the role of LBP and CD14 in models of endotoxemia and infection.Keywords
This publication has 12 references indexed in Scilit:
- Blockade of CD14 Increases Shigella-Mediated Invasion and Tissue DestructionThe Journal of Immunology, 2000
- Inhibition by a CD14 monoclonal antibody of lipopolysaccharide binding to murine macrophagesInnate Immunity, 1999
- Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxinProceedings of the National Academy of Sciences, 1998
- Targeted Deletion of the Lipopolysaccharide (LPS)-binding Protein Gene Leads to Profound Suppression of LPS Responses Ex Vivo, whereas In Vivo Responses Remain IntactThe Journal of Experimental Medicine, 1997
- Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infectionNature, 1997
- Antibodies against CD14 protect primates from endotoxin-induced shock.Journal of Clinical Investigation, 1996
- Resistance to Endotoxin Shock and Reduced Dissemination of Gram-Negative Bacteria in CD14-Deficient MiceImmunity, 1996
- Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock.Proceedings of the National Academy of Sciences, 1993
- Structure and Function of Lipopolysaccharide Binding ProteinScience, 1990
- CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding ProteinScience, 1990